Pfizer's Hympavzi showed superior bleed control in hemophilia A and B patients with inhibitors, reducing bleeding rates and ...

Empagliflozin has kidney protective effects and reduces heart failure outcomes across baseline kidney function among patients ...

A study published in JAMA Surgery involving nearly 500,000 surgeries among U.S. veterans found that patients taking SGLT2 ...

For high-risk patients with type 2 diabetes, oral semaglutide reduced risk for major cardiovascular and ischemic limb-related ...

Empagliflozin use in patients with type 2 diabetes (T2D) has not been shown to have a higher risk of urinary tract cancers ...

Rising demand for eco-friendly detergents and health supplements drives glucaric acid market growth amid increasing consumer wellness awareness globally.Austin, June 26, 2025 (GLOBE NEWSWIRE) -- The ...

TheracosBio today announced that BRENZAVVY® (bexagliflozin), an FDA-approved oral sodium-glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes, is available to customers at ...

In a significant showcase for investors, BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will announce major advancements to its industry-leading oncology ...

Neoadjuvant cobolimab and dostarlimab followed by surgery and adjuvant dostarlimab may confer benefits over perioperative pembrolizumab in patients with high-risk, resectable melanoma.

A phase 2 trial evaluated the efficacy and safety of lorundrostat in hypertensive patients with chronic kidney disease (CKD) and albuminuria.